Martingale Asset Management L P Buys 23,890 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Martingale Asset Management L P boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 27.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,967 shares of the biopharmaceutical company's stock after buying an additional 23,890 shares during the period. Martingale Asset Management L P owned approximately 0.09% of Catalyst Pharmaceuticals worth $2,316,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $65,000. KBC Group NV boosted its holdings in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalyst Pharmaceuticals in the 4th quarter worth about $134,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ CPRX traded up $0.38 during midday trading on Tuesday, reaching $23.18. The company had a trading volume of 626,850 shares, compared to its average volume of 1,379,078. The stock has a market cap of $2.82 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16. The firm's fifty day moving average price is $22.62 and its 200-day moving average price is $22.04.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Robert W. Baird boosted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Stephens restated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Bank of America reiterated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $32.29.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.